TIDMIXI

RNS Number : 5029Z

IXICO plc

21 September 2020

IXICO plc

("IXICO" or the "Company")

IXICO selected to support Alzheimer's trial

Global Alzheimer's Platform Foundation selects IXICO for innovative Bio-Hermes trial

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that is has been selected by the Global Alzheimer's Platform Foundation(R) (GAP) to support GAP's planned Bio-Hermes trial. IXICO will apply its expertise to collect Positron Emission Tomography (PET) brain scans in qualifying imaging centres participating in Bio-Hermes and provide analysis of the scans.

Bio-Hermes' core purpose is development of a bio-sample database to investigate biomarkers on a head-to-head basis in conjunction with medical history elements. The Bio-Hermes trial will include 1,000 volunteers over the age of 60 screened for Preclinical Alzheimer's Disease, Prodromal AD, or Mild Dementia AD. Observational biomarker studies consistently suggest that amyloid deposition and tau deposition in neurofibrillary tangles in the brain may be the sentinel events in Alzheimer's Disease pathology. In the Bio-Hermes trial, Avid Pharmaceuticals' Amyvid(TM) will be used as the radioactive diagnostic agent to estimate <BETA>-amyloid neuritic plaque density.

This contract does not have significant impact on management's expectations of performance for the year, but will contribute to the Company's already strong year end order book.

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"We are delighted to be selected by GAP as their prime choice for the analysis of PET scans in the Bio-Hermes trial. With a reinvigorated level of interest in Alzheimer's disease, we are excited about the prospects of long-term collaboration with our colleagues at GAP who share our own commitment to reducing the time, cost, and risk for Alzheimer's Disease trials. The support provided by IXICO staff on Bio-Hermes is an important commercial development in enhancing IXICO's market position in neuroimaging for Alzheimer's Disease clinical trials."

John Dwyer, President of Global Alzheimer's Platform Foundation (GAP), commented:

"Our collaboration with IXICO for neuroimaging and AI is a key element of GAP's innovative Bio-Hermes trial, which is taking a novel approach to provide digital and blood biomarker results for comparison across cognitively normal and impaired individuals. We've also committed to ground-breaking levels of minority participation so that future treatment breakthroughs can benefit everyone impacted by Alzheimer's."

For further information please contact:

 
 IXICO plc                                                   +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive 
  Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                           +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Michael F Johnson / Russell Kerr 
  (Sales) 
 
 Walbrook PR Ltd                                            + 44 (0)20 7933 8780 
 Paul McManus / Lianne Cawthorne                            IXICO@walbrookpr.com 
  / 
 Alice Woodings 
 Global Alzheimer's Platform Foundation Media                       408-466-5952 
 Pamela Larkin                                   or pamelalarkin@rational360.com 
 
 

About the Global Alzheimer's Platform Foundation (GAP)

The Global Alzheimer's Platform Foundation (GAP) is a patient-centric nonprofit dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Research centers across the US and Canada are part of the growing GAP Network (GAP-Net). GAP supports GAP-Net research centers by assisting with study start up and recruitment activities, promoting diversity in research studies, and offering national programs that champion brain health and the citizen scientists who make research possible.

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKKKBNFBKKCCB

(END) Dow Jones Newswires

September 21, 2020 02:00 ET (06:00 GMT)